Mizuho Upgrades Maze Therapeutics (NASDAQ:MAZE) to Strong-Buy

Maze Therapeutics (NASDAQ:MAZE) was upgraded by stock analysts at Mizuho to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports.

A number of other research firms have also commented on MAZE. Lifesci Capital raised Maze Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Weiss Ratings reiterated a “sell (d)” rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. HC Wainwright restated a “buy” rating on shares of Maze Therapeutics in a research note on Wednesday, January 28th. Guggenheim upped their price objective on Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Finally, Wells Fargo & Company began coverage on shares of Maze Therapeutics in a research note on Thursday, December 4th. They issued an “overweight” rating and a $55.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $54.63.

Maze Therapeutics Stock Performance

Maze Therapeutics stock traded down $2.48 during trading hours on Wednesday, reaching $49.36. 193,029 shares of the company’s stock traded hands, compared to its average volume of 454,203. Maze Therapeutics has a fifty-two week low of $6.71 and a fifty-two week high of $52.86. The firm has a market capitalization of $2.37 billion, a price-to-earnings ratio of -2.36 and a beta of 4.47. The firm’s 50 day moving average is $44.61 and its 200-day moving average is $35.34.

Insider Transactions at Maze Therapeutics

In related news, CMO Harold Bernstein sold 45,000 shares of the stock in a transaction on Monday, December 29th. The stock was sold at an average price of $40.56, for a total value of $1,825,200.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Atul Dandekar sold 72,400 shares of Maze Therapeutics stock in a transaction on Monday, December 29th. The stock was sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the transaction, the insider directly owned 10,503 shares of the company’s stock, valued at approximately $426,001.68. This trade represents a 87.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 230,000 shares of company stock worth $9,768,292.

Hedge Funds Weigh In On Maze Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MAZE. Frazier Life Sciences Management L.P. lifted its stake in Maze Therapeutics by 10.6% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock valued at $56,040,000 after purchasing an additional 438,274 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Maze Therapeutics by 318.0% during the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after buying an additional 2,390,713 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Maze Therapeutics by 27.1% during the fourth quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company’s stock worth $70,307,000 after buying an additional 362,060 shares in the last quarter. Woodline Partners LP lifted its stake in shares of Maze Therapeutics by 10.0% in the 3rd quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock valued at $26,843,000 after acquiring an additional 94,529 shares during the last quarter. Finally, Marshall Wace LLP boosted its holdings in shares of Maze Therapeutics by 9.0% during the 4th quarter. Marshall Wace LLP now owns 847,472 shares of the company’s stock valued at $35,111,000 after acquiring an additional 69,771 shares in the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.